Monoallelic expression determines oncogenic progression and outcome in benign and malignant XXXX .

@entity1 @entity1313 @entity5 @entity146 @entity876 @entity818 @entity2215
Although monoallelic expression (MAE) is a frequent genomic event in normal tissues, its role in tumorigenesis remains unclear. Here we carried out single-nucleotide polymorphism arrays on DNA and RNA from a large cohort of pediatric and adult @entity1313 tissues to determine the genome-wide rate of MAE, its role in specific @entity5 -related genes, and the clinical consequences of MAE in @entity1313 . We also used targeted genotyping to examine the role of @entity5 -related genes in @entity1313 development and specifically examined the clinical consequences of MAE at @entity876 and @entity818 . The genome-wide rate of @entity5 MAE was higher than in previously described normal tissue and increased with specific @entity5 grade. Oncogenes, but not @entity5 suppressors, exhibited significantly higher MAE in high-grade compared with low-grade @entity5 . This method identified nine novel genes highly associated with MAE. Within @entity5 -related genes, MAE was gene specific; @entity2215 was most significantly affected, with a higher frequency of MAE in adult and advanced @entity5 . Clinically, MAE at @entity876 exists only in mutated @entity5 and increases with @entity146 . MAE toward the normal allele at @entity818 conferred worse survival even in @entity818 mutated @entity5 . Taken together, our findings suggest that MAE is @entity5 and gene specific, frequent in @entity1313 subtypes, and may be associated with @entity5 progression/ @entity146 . Further exploration of MAE at relevant genes may contribute to better understanding of @entity5 development and determine survival in @entity1313 @entity1 .
